Cancer therapeutics startup Abdera Therapeutics emerged from stealth with $142M in venture funding through a combined Series A and B round.
The firm intends to use the proceeds to develop radiopharmaceuticals
and advance promising therapeutics to the human clinical trial stage in
2024.
- CEO
Lori Lyons-Williams said, "Radiopharmaceuticals hold the potential to
transform the treatment of cancer, but the ability to finely tune
radioisotope delivery to the tumor while sparing healthy tissue remains a
major challenge for this class of drugs."
- In addition to the fresh funding, the Canadian biotech startup had previously raised a CA$8M ($5.9M) seed round in January 2021, per Crunchbase.
- Versant Ventures and Amplitude Venture Capital led the Series A tranche, while venBio Partners led the Series B round.
- Northview Ventures, adMare BioInnovations, and AbCellera participated in the Series A round.
- The Series B round saw participation from Viking Global Investors, Qiming Venture Partners USA, and RTW Investments.
